In recent years, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have achieved continuous breakthroughs in the treatment of diabetes and obesity, reshaping the global therapeutic paradigm. With the widespread adoption of peptide-based GLP-1RAs and the rapid emergence of small-molecule GLP-1RAs, GLP-1 therapies are evolving from a focus on “glycemic control” toward comprehensive metabolic management. Among them, small-molecule GLP-1RAs—offering the advantages of oral convenience and scalable manufacturing—hold great promise in enhancing patient adherence and advancing personalized management of metabolic diseases. Leveraging its fully integrated, end-to-end CRDMO platform, WuXi AppTec has long been deeply involved in and empowering the global discovery, development, and manufacturing of GLP-1 therapies. WuXi AppTec continues to help accelerate the innovation and clinical translation of next-generation GLP-1 therapeutics, bringing transformative treatments to patients around the world.

Over the past few years, GLP-1RAs have transformed care for type 2 diabetes mellitus (T2DM) and obesity. By enhancing glucose-stimulated insulin secretion, suppressing glucagon, and curbing appetite to support weight loss, these therapies deliver sustained glycemic control and meaningful clinical benefits. Their success has reset clinical expectations, improving metabolic and cardiovascular outcomes and ushering in a new era that addresses not only blood glucose but also the broader drivers of metabolic disease.

While peptide-based GLP-1RAs continue to elevate patient outcomes, the emergence of orally available, small-molecule GLP-1RAs opens a complementary frontier. These agents are chemically stable, readily manufactured at scale, and suitable for oral dosing without permeation enhancers, which expands accessibility and convenience for patients worldwide.

Mechanistically, small-molecule GLP-1RAs recapitulate the beneficial signaling of peptide analogs through novel receptor-engagement strategies, including allosteric modulation, biased agonism, and selective activation of G-protein–mediated pathways. Supported by high-resolution structural insights, these approaches enable precise control of receptor signaling while maintaining favorable pharmacokinetics and oral bioavailability.

The emergence of small-molecule GLP-1RAs is opening new possibilities for combination therapy. Their oral, food-independent formulation enables convenient co-administration with approved oral agents such as SGLT2 inhibitors or metformin to create fixed-dose combination regimens. These combinations may deliver synergistic benefits in glucose control, weight management, and cardiometabolic protection, while offering multi-target, multi-pathway modulation to help reduce cardiovascular and renal risks at their source. At the same time, a simplified dosing regimen can further improve long-term treatment adherence among patients.

Currently, one of the most advanced oral small-molecule GLP-1RAs is in Phase 3 clinical trials for patients with type 2 diabetes (T2DM). Published clinical data have demonstrated significant reductions in both A1C and body weight. The therapy is expected to be submitted for regulatory approval worldwide in 2026.

Importantly, small-molecule and peptide-based GLP-1RAs should not be viewed as competing alternatives but as complementary therapeutic options. Together, they expand the spectrum of treatment possibilities, enabling physicians to tailor personalized regimens based on patients’ characteristics, lifestyles, and care needs—ultimately improving clinical outcomes and enhancing quality of life.

WuXi AppTec’s Chemistry platform adopts an integrated, end-to-end CRDMO model that seamlessly connects drug discovery (R), development (D), and commercial manufacturing (M). Covering every stage from early discovery to large-scale production, the platform is committed to providing global partners with fast, flexible, efficient, and reliable one-stop small-molecule, oligonucleotides, peptides, and complicated conjugates drug development solutions.

According to WuXi AppTec’s Investor Day on September 2025, nearly 100 GLP-1 receptor agonists are currently in clinical development or already on the market globally, with 23 supported by WuXi AppTec’s chemistry platform. Looking ahead, WuXi AppTec will continue to support the advancement of next-generation GLP-1 therapies through its unique integrated, end-to-end CRDMO platform, helping bring innovative therapeutic options to patients worldwide.